Blinatumomab consolidation in children with high-risk first-relapse B-cell precursor acute lymphoblastic leukemia: final 5-year follow-up analysis of a randomized multicenter phase 3 study
Open Access
- 13 November 2025
- journal article
- letter
- Published by Springer Nature in Leukemia
- Vol. 40 (1) , 230-234
Abstract
No abstract availableKeywords
Funding Information
- Amgen (Not applicable)
- Amgen (Not applicable)
This publication has 8 references indexed in Scilit:
- Blinatumomab in Standard-Risk B-Cell Acute Lymphoblastic Leukemia in ChildrenNew England Journal of Medicine, 2025
- Safety and Feasibility of Blinatumomab As Frontline Therapy for Pediatric Patients with B-Acute Lymphoblastic Leukemia and Lymphoma: St. Jude Total Therapy Study XVIIBlood, 2024
- Pediatric Patients with High-Risk B-Cell ALL in First Complete Remission May Benefit from Less Toxic Immunotherapy with Blinatumomab - Results from Randomized Controlled Phase 3 Trial AIEOP-BFM ALL 2017Blood, 2023
- Improved survival and MRD remission with blinatumomab vs. chemotherapy in children with first high-risk relapse B-ALLLeukemia, 2022
- Blinatumomab overcomes poor prognostic impact of measurable residual disease in pediatric high‐risk first relapse B‐cell precursor acute lymphoblastic leukemiaPediatric Blood & Cancer, 2022
- Risk factors and outcomes in children with high-risk B-cell precursor and T-cell relapsed acute lymphoblastic leukaemia: combined analysis of ALLR3 and ALL-REZ BFM 2002 clinical trialsEuropean Journal of Cancer, 2021
- Effect of Blinatumomab vs Chemotherapy on Event-Free Survival Among Children With High-risk First-Relapse B-Cell Acute Lymphoblastic LeukemiaJAMA, 2021
- How I treat relapsed childhood acute lymphoblastic leukemiaBlood, 2012